Figure 1
From: Drotrecogin alfa (activated): real-life use and outcomes for the UK
Primary results of matched cohort analyses on acute hospital mortality versus PROWESS at 28 days. PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.